10:35 AM EST - BELLUS Health Inc. : Announced that Dr. Denis Garceau, BELLUS Health's Senior Vice President, Drug Development, will present the Company's lead drug candidate for the treatment of chronic cough, BLU-5937, at the 2018 International Cough Symposium in London, England on Wednesday June 27. BELLUS Health Inc.
shares T.BLU are trading unchanged at $0.53.
